Gao et al. (2021) showed that MEG3 enhances the anti-tumor activity of curcumin in gemcitabine-resistant NSCLC cells through the PTEN pathway. A study by El-Khazragy et al. (2020) revealed that the level of MEG3 is used as a biomarker to predict cisplatin resistance of OC. Liu et al. (2018a) clarified that MEG3 enhances the radiosensitivity of TC cells to 131I by sponging miR-182 and inducing tumor cell apoptosis. The gene discussed is MEG3; the disease is neoplasm.